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Abstract
Recent advances in therapeutically important cell fate reprogramming fuelled a renaissance in the use of mRNA-
based gene vectors. Thus, mRNA vectors were successfully employed to induce lasting epigenetic changes in
various target cells making them short-listed vector candidates for the manufacture of therapeutic engraftment
materials for autologous transplantation, artificial human tissues for drug discovery via high-throughput screening
projects and also for therapeutic cell trans-differentiation directly in the human body. De-differentiation of cells into
‘induced pluripotent stem cells’, transgene-directed differentiation and trans-differentiation require the simultaneous
delivery of a number of regulatory factors, and, favourably, potent reprogramming vector cocktails can be
straightforwardly assembled from a selection of mRNA species. In addition, several proteins can be conveniently
expressed from a single mRNA using internal ribosome entry sites (IRESes) or, alternatively, fusion proteins
supplemented with ‘polypeptide-cleaving’ ribosome skipping sequences. This review is focused on the design and
production of cell-fate changing mRNAs.
Keywords: Epigenetic reprogramming; Forward programming;
mRNA gene vectors; Induced pluripotent stem cells;
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Background
One of the pivotal discoveries in molecular medicine was made by
Takahashi and Yamanaka in 2006, who showed that stable epigenetic
reprogramming of mammalian cells could be achieved using the
delivery of just a few transgenes coding for regulatory factors [1].
Initially, the new approach was used only for de-differentiation to
generate artificial stem cells, so-called ‘induced pluripotent stem cells’
(iPS cells), from differentiated cells. However, later it became apparent
that gene transfer can also be used to direct, to ‘coax’, stem cells,
including iPS cells, into differentiation in vitro [2,3]. Such ‘gene-
transfer-forced’ differentiation was called ‘forward programming’. The
employment of gene transfer to achieve cell differentiation
considerably expanded the possibilities offered by traditional in vitro
differentiation protocols relying on protein and small molecule factors
in the cell culture medium. Finally, it was discovered that on some
occasions gene transfer can be used for the direct reprogramming of
differentiated cells in order for them to become differentiated cells of
another type [4]. Epigenetic changes of this type are classified as
‘transdifferentiation’. The above modes of epigenetic transformation,
which can be achieved through gene transfer, are therapeutically
important because of the possibilities they open for regenerative
medicine and high-throughput drug screening projects with artificial
human tissues. For example, a common scenario in regenerative
medicine involves the imbedding of differentiated iPS cells, forward-
programmed stem cells or directly trans-differentiated cells, which
were originally obtained from individual patients, into a suitable
scaffold for subsequent autologous therapeutic transplantation back
into individual cell donors.
A variety of gene vectors can be used to deliver transgenes to cause
epigenetic shifts in recipient cells. Recently, gene vectors based on
synthetic messenger RNA (mRNA) have gained prominence as an
effective and safe tool for epigenetic reprogramming of cells. Vectors
based on mRNA were well-tested, as over the last 20 years substantial
experience has been acquired in the use of these vectors for the
delivery of foreign genes into a variety of mammalian cells [5,6].
Crucially, in contrast to most other types of non-viral gene vehicles,
mRNA vectors do not need to pass through the barrier of the bi-
membrane nuclear envelope to enter nucleoplasm for successful
transgene expression. This property has multiple beneficial
implications for induced epigenetic switches. Indeed, standard mRNA
vectors: 1) achieve rapid transgene expression; 2) are effective for gene
transfer into slowly dividing and non-dividing cells; 3) evade silencing
at a transcriptional level, which is an impediment typically associated
with DNA vectors; 4) are incapable of either integrating into
chromosomes or long-term episomal maintenance and, thus, do not
leave a permanent genetic trace after epigenetic modification of target
cells; 5) offer improved transfection efficiency in comparison to DNA-
mediated non-viral gene delivery as the latter relies either on the short
window of the nucleoplasm’s accessibility during mitosis or on as yet
inefficient artificial molecular prop-ups for the passage through the
nuclear envelope. However, the efficient and reliable manipulation of
cell fate still faces many practical challenges, many of which can be
addressed by bespoke and optimized gene vectors. Thus, the
employment of mRNA-based gene vectors in the future medical
applications of epigenetic engineering requires refinement of their
design and production, which we review below.
Design and production of vector mRNA
mRNA directs the biosynthesis of specific proteins in cells by
translation. Thus, clearly, mRNA is the core component of any
mRNA-based gene vectors. For eukaryotic translation to start, the
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formation of a translation complex is required, which, in addition to
mRNA, consists of some protein initiation factors, the initiator tRNA
and the 40S ribosomal subunit. A molecular structure called a ‘cap’ at
the upstream mRNA end is important for the translation of many
functional eukaryotic mRNAs with some exceptions, which we discuss
below. In general, a standard cap has the structure m7G(5’)ppp(5’)N,
which includes an unusual 5’-5’ tri-phosphate bridge between the
terminal m7-guanosine and the rest of the mRNA. The well-
established functions of the cap are the protection of mRNA from
RNAses, export of mRNA from the nucleus and translation initiation.
‘Natural’ formation of the cap in the nucleus involves the activities of
RNA terminal phosphatase, RNA guanylyl transferase and RNA
guanine methylase, with the latter enzyme being responsible for the
methylation of the nitrogen atom in position 7 of the guanine base [7].
Another common structural feature of mRNAs is a homopolymeric
sequence of A nucleotides known as 3’-poly(A) tail. Similarly to the
cap, the functions of the poly(A) tail include stimulation of translation,
protection of mRNA from degradation and export of mRNA from the
nucleus. ‘Natural’ poly(A) tails are formed through a concerted action
of a number of enzymatic activities, with nucleotides being added
through polyadenylate polymerase (PAP) activity [8].
While both the cap and the poly(A) tail play a role in the export of
mRNA out of the nucleus, natural eukaryotic mRNA might contain
some additional signals for its export out of the nucleus (e.g., ‘post-
transcriptional response elements’, PRE). In contrast to the cap and
the poly(A) tail, which are normally essential for mRNA stability and
initiation of translation, the presence of such additional nuclear export
signals is not required within artificial mRNA vectors, as they are
designed to be exclusively cytoplasmic. Similarly, the delivery of
artificial mRNA directly into the cytoplasm necessitates its synthesis in
a spliced form with possible omission of redundant splicing signals in
artificial mRNA vectors.
Segments of mRNA encoding an amino acid sequence are called
‘cistrons’. In eukaryotic translation of nuclear-sourced mRNAs, AUG
is the start codon and UAG (amber), UGA (opal) and UAA (ochre)
are the stop codons. In active eukaryotic mRNAs, the start codon
AUG is imbedded within the ‘Kozak consensus sequence’. The Kozak
sequence is one of the key translation initiation signals in eukaryots
and, as such, is an important element of artificial mRNA vectors. One
of the efficient versions of the Kozak sequence is 5’-
GCCGCCAUGG-3’ where AUG is the start codon.
Synthesis of vector mRNA
The synthesis of mRNA using methods of traditional polymer
chemistry is time-consuming and inefficient. Therefore, DNA-
template directed polymerase-led transcription processes are normally
used for the generation of artificial mRNA gene vectors.
Eukaryotic cells harbour all the elements of transcription machinery
and, as an example, yeast cells can certainly be used as mRNA vector
factories. However, the drawbacks of such an intact-cell-based
approach for the generation of mRNA are a relatively low mRNA yield
and a need to purify specific mRNAs from a multitude of
contaminants including biochemically-similar undesired mRNAs. In
contrast, cell-free in vitro transcription systems can provide an ultra-
high yield mRNA production and also drastically reduce the number
of contaminating molecules. Although mRNA that is active in human
cells is required, the standard choice for in vitro synthesis of pre-
designed mRNA is a prokaryote-based system, as transcription
machinery in eukaryotes is more complex and, therefore, more
difficult to adapt to in vitro use. Particularly attractive are
bacteriophage-derived transcription systems, which offer superior
productivity, the simplicity of DNA-template elements required for
the bacteriophage-encoded transcription machinery and the ready
availability of RNA polymerases. Thus, a typical strategy is employing
prokaryotic enzymes like RNA polymerases of bacteriophages T7, T3
or SP6 for in vitro synthesis of the major portion of mRNA, followed
by the introduction of appropriate add-ons and modifications, which
make the resultant mRNA suitable for efficient expression in
eukaryotic cells. Common commercially available systems include
mMESSAGE mMACHINE® kit and a more sophisticated mMESSAGE
mMACHINE® T7 Ultra kit (Invitrogen Life Technologies-Ambion),
both of which exploit bacteriophage T7 RNA polymerase. Linear DNA
templates, such as plasmid fragments or PCR amplicons are preferred
because the high processivity of bacteriophage RNA polymerases
could result in undesired extra-long multimeric transcripts produced
by repeated cycling of RNA polymerases along circular templates [9].
Normally, prokaryotic mRNAs are not capped or polyadenylated.
Therefore, the addition of both the cap and poly(A) tail to synthetic
mRNA is required for its successful translation in eukaryotic cells. To
cap RNA in vitro, Invitrogen Life Technologies-Ambion recommends
supplementation of the transcription with an analogue of 7-methyl
guanosine (5’) triphospho-(5’) guanosine. The name of the latter
compound is abbreviated as m7G(5’)ppp(5’)G and its analogue is
known as ‘anti-reverse cap analogue’ (ARCA). Indeed,
m7G(5’)ppp(5’)G can be used by RNA polymerase as a building block
for synthesized mRNA. As desired, due to space constraints,
m7G(5’)ppp(5’)G can only be incorporated into the first position of
the nascent transcript. However, bacteriophage-T7-based in vitro
transcription system installs m7G(5’)ppp(5’)G in two alternative
orientations (incorporating either G or m7G into the nucleotide
chain), with only one of the orientations (with the chain-incorporated
G) corresponding to the natural translation-competent cap. Thus,
chemical modification of m7G(5’)ppp(5’)G is used to obtain ARCA
that is suitable for directional insertion. The desired translation-
compatible modification can be achieved, for example, by replacement
of one of the hydroxyl groups in the m7G moiety of m7G(5’)ppp(5’)G
with a methoxyl group to block the RNA chain growth via this group.
So, the employment of ARCA ensures a single and correct orientation
of the cap in the synthesized RNA molecules, thus increasing the
activity of the obtained mRNA in translation.
One of the structural features of the eukaryotic mRNA is a 3’-
poly(A) tail of at least 30 nucleotides. Supplementation of synthetic
mRNA with poly(A) is often important for the stability of mRNA and
for the efficiency of mRNA translation in target cells.
One possible strategy for the addition of the poly(A) tail is to mimic
the natural process of poly(A) synthesis in mRNA. In eukaryotes, the
formation of the natural poly(A) tail in vivo requires a polyadenylation
start signal sequence within template DNA. The mechanics of
polyadenylation initiation is currently not entirely understood. The
sequences 5’-AAUAAA-3’ or 5’-AUUAAA-3’ are often found in
polyadenylation signals [10]. They are located 10-30 nucleotides
upstream of the poly(A) attachment site, are highly conserved but not
strictly required for the polyadenylation. A role in polyadenylation
initiation might also belong to the secondary structures within RNA
[11]. In general, eukaryotic polyadenylation is somewhat complicated
for reconstruction in vitro, with polyadenylate polymerase providing
just one of the required enzymatic activities in the polyadenylation
complex. Therefore, prokaryotic E.coli-derived template-independent
Citation: Tolmachov OE, Tolmachova T (2015) Design and Production of mRNA-based Gene Vectors for Therapeutic Reprogramming of Cell
Fate. Gene Technology 4: 117. doi:10.4172/2329-6682.1000117
Page 2 of 9
Gene Technology
ISSN:2329-6682 GNT, an open access journal Volume 4 • Issue 1 • 1000117
poly(A) Polymerase (EcPAP) is often a preferred tool to furnish
artificial mRNA with a poly(A) in a simple in vitro procedure [12].
The alternative practical strategy for attachment of the 3’-poly(A) tail
to the synthetic mRNA is to generate the tail together with the rest of
the RNA during transcription via inclusion of the poly(A) sequence
within the DNA template [13].
In many practical situations, a weak point of synthetic mRNA gene
vectors is their instability. Encouragingly, it was shown that the
instability can be substantially reduced through the incorporation of
specific sequences from the 3’ untranslated terminal region (3’-UTR)
of Venezuelan Equine Encephalitis Virus (VEEV) into artificial
mRNAs [14].
Purification of mRNA after its synthesis
After in vitro transcription, attachment of the synthetic cap and
polyadenylation, synthetic mRNA need to be purified. The standard
steps are digestion of the DNA template with DNAse I, RNA
precipitation with LiCl and washing with 70% ethanol. After digestion
it is important to inactivate DNAseI, for example, by addition of a
chelating stop solution and heating. The step of RNA precipitation
with LiCl is particularly useful because the precipitation is selective;
that is, NTPs, DNA and substantial fraction of proteins are not
precipitated [15]. However, epigenetic engineer should be aware that
mRNAs with a highly compact 3D structure might be poorly
precipitated by LiCl. In this case, the employment of a chaotropic
agent such as formaldehyde might be required to destroy secondary
structures of the heavily folded mRNA and, thus, to improve its
precipitation.
Alternative methods, which might be useful for high-throughput or
large-scale purification and concentration of synthetic mRNA, include
gel filtration, ultrafiltration, binding to silica-gel membranes,
treatment with StrataCleanTM resin and dialysis. StrataCleanTM resin
(Agilent Technology) is a silica-based resin with negatively charged
hydroxyl groups capable of binding macromolecules such as positively
charged proteins. Production of ultra-pure mRNA might also rely on
poly(A)-targeted oligo(dT) affinity columns and cap-targeted affinity
columns with immobilised cap-binding eukaryotic initiation factor 4E
(eIF4E). Column affinity-based purification systems can be substituted
for affinity-based paramagnetic beads, a robot-friendly format.
Dialysis can be particularly important for the removal of small ionic
impurities from the mRNA preparations prior to gene transfer by
electroporation because ionic impurities can be responsible for
undesired electric current, which increases the temperature of the
electroporated cells and, hence, decreases their viability. Small volume
dialysis can be conveniently performed in Slide-A-LyzerR MINI
Dialysis units (Thermo Scientific).
The RNA concentration can be established and the size
homogeneity of mRNA can be rapidly confirmed with small sample
consumption using microfluidic chips on BioanalyzerTM system
(Agilent Technology). An alternative way to quantify mRNA is to use
RNA-specific fluorescent ligands, e.g., in conjunction with purpose-
designed QubitTM fluorometer (Invitrogen Life Technologies).
For the isolation of small amounts of mRNA, e.g., from cells and
tissues, ‘carrier RNA’ can be employed to improve the binding of
mRNA to column matrices, efficient precipitation and/or for
protection from RNAses. A reasonable choice for the carrier RNA is
poly(I), a polymer of inosine. This nuclear acid is genetically inert
because, although III triplets can be interpreted by the translation
machinery as a glycine codon GGG, poly(I) lacks the Kozak
translation start signal. Alternative translationally-inert carriers are
glycogen, the cocktail of yeast tRNAs and the cocktail of E.coli
ribosomal RNAs [16]. Commercial suppliers, which produce mRNA
vectors and cocktails of mRNA, include Stemgent, System Biosciences
(SBI) and Stemedica Cell Technologies.
In contrast to DNA vectors, many of which contain plasmid DNA
generated in bacteria, mRNA vectors, which are produced using in
vitro transcription systems or eukaryotic cells, have a reduced chance
of contamination with immunogenic and toxic bacterial
lipopolysaccharides (LPS). Clearly, this is particularly advantageous in
those therapeutic applications of mRNA-based vectors, which involve
intra-body gene delivery.
Use of non-canonical mRNAs as gene vectors
Some eukaryotic mRNAs can get involved in translation not only
through the cap structure but also through internal ribosome entry
sites (IRESes) in their 5’-untranslated terminal regions (5’-UTRs).
Some researchers consider such 5’-UTR IRESes as sufficiently different
from the bona fide inter-cistron IRESes to warrant them a special
name, cap-independent translational enhancers (CITEs) [17]. Some
CITEs appear to be reasonably efficient, attracting up to three
translation initiation complexes on a single mRNA [18]. It is difficult
to define a specific sequence motif for CITEs and they are presumed to
act through secondary structures. Research on 5’-UTR sequences also
shows that on some occasions secondary structures associated with 5’-
UTR IRESes can impede ‘ribosome scanning’ through RNA and so can
interfere with cap-dependent translation [19]. Clearly, the interplay
between cap-dependent and cap-independent initiation of translation
can be a control point to regulate gene expression, e.g., for tissue-
specific expression [20] or a response to environmental stimuli [13].
As vector mRNA is often produced in vitro, it is straightforward to
engineer a CITE element in its 5’-UTR to avoid the in vitro capping
step. Alternatively, both the cap and a 5’-UTR IRES can be employed,
e.g., emulating genomic transcripts of the wild type HIV-1 virus [21].
Tissue-specificity of transgene expression is often an important
therapeutic factor in genetic medicine, so CITEs can potentially be
exploited in the design of tissue-specific mRNA vectors.
Histone mRNAs are notorious for lacking poly(A) tails and instead
containing secondary structures at their 3’-ends. Clearly, these or
similar structures can be used to substitute for a poly(A) tail in mRNA
vectors. It is possible that histone-style 3’-ends of mRNA can provide
superior protection from RNases and, thus, enhance mRNA stability
and ensure more efficient protein synthesis.
Multigene delivery using mRNA vectors
Typically, epigenetic reprogramming requires the simultaneous
expression of several transgenes. Another common scenario for the
simultaneous delivery and expression of several messages is the
combined transfer of reprogramming genes and a marker gene. In
general, the strategies to unite the delivery of several messages include
assembly of mRNA cocktails, engineering of polycistronic mRNA
vectors and construction of mRNAs coding for fusion proteins.
Fortuitously, mRNA vectors offer the benefits of straightforward
combination of several messages in a single multi-gene cocktail. For
example, spiking of mRNA for ecotropic retroviral receptor mCAT-1
with mRNA for a marker protein GFP was successfully used to
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monitor the efficiency of mCAT-1 gene transfer [22]. The same co-
delivery strategy can be applied to the transfer of cocktails of
reprogramming mRNAs, which can be supplemented with an ‘internal
control’ marker gene mRNA. Bouquets of reprogramming mRNAs
can contain multiple synthetic mRNAs with a broad range of
concentrations and also can be supplemented with mRNA-extracts
from specific mammalian cell populations.
Engineering of polycistronic mRNA is often a convenient strategy
to combine several reasonably short messages. Translation of a
downstream cistron in eukaryots can occur only after re-initiation on
IRES sequences positioned between the cistrons. In artificial
constructs, an IRES element is typically embedded within a sequence
of about 500 bases. The translation initiation efficiency of the IRES
elements can be controlled through modification of the size of the
inter-cistronic sequence [23]. Multiple cistrons were previously
successfully assembled within a single efficient IRES-joined
transcription module [24]. As in the mRNA-cocktail-based gene co-
delivery strategy, one of the common scenarios in polycistronic gene
co-delivery is a combination of a ‘payload gene’ and an easily detected
marker as an ‘internal control’ for convenient gauging of the level of
the ‘payload gene’ expression. However, the epigenetic engineer
should be aware that in IRES-based gene co-delivery, the expression
level of the upstream transgene is not necessarily equal to the
expression level of the downstream transgene.
Another feasible approach to combine several messages for
concurrent expression is to design and to generate a single mRNA for
a fusion protein, e.g., the ‘payload protein’ fused with a protein
possessing an easily detectable activity. Fusion proteins can be split
into individual polypeptide chains using viral ‘ribosome skipping
elements’ like 2A peptide sequence [25].
Gene co-delivery with synthetic mRNA vectors compares
favourably to co-delivery using competing ‘hit-and-run’ transfer
systems which leave no ultimate genetic residue in recipient cells,
namely, cell transduction with virally packaged RNAs and direct
transfer of proteins to cells relying on ‘protein transduction domains’
(PTDs). Indeed, all viral vectors have nucleic acid size packaging
constraints preventing encapsidation of extra-long polycistronic
RNAs. Furthermore, the direct transfer of several proteins into cells
necessitates equipping each of the proteins with an individual PTD, a
laborious and time-consuming procedure.
The choice of the marker gene
Marker genes are required to estimate the efficiency of gene delivery
and expression. The expression of marker genes can also be a useful
tracer of the delivery area after in vivo gene transfer. The transiency of
mRNA-mediated transgene expression means that the detection time
frame is fairly short. Therefore, markers with an extended period of
evaluation, such as cellular drug-resistance markers, are often not
suitable for measuring the efficiency of mRNA-based gene delivery. In
contrast, genes for enzymes and fluorescent proteins are particularly
convenient.
Luciferases are enzymes, which catalyse the conversion of a
substrate (luciferin) into a product (oxyluciferin) with concomitant
emission of light. The commonly used luciferases originate from the
North American firefly Photinus pyralis and sea pansy Renilla
reniformis. Luciferase activity can be detected using specialized
luminometers either in a solution or within a tissue. Other enzymes,
for example, chloramphenicol acetyl transferase (CAT) and E.coli β-
galactosidase, can also be employed to read-out the efficiency of
mRNA delivery. Secreted enzymes, such as secreted luciferase, allow
time-course measurements of the transgene expression in the same
population of live cells.
Currently used fluorescent proteins are mostly derived from the
green fluorescent protein (GFP) of the jellyfish Aequoria victoria and
dsRed protein of coral Discosoma sp. Fluorescence can be read-out by
both microscopy and fluorescence activated cell sorting (FACS).
Intracellular targeting of fluorescent proteins is often used to increase
the specificity of microscopic detection and quantitative examination
by automated high-throughput microscopy and image analysis (e.g.,
using the software of Cellomics robot or Definiens software package).
The available targeting motifs include nuclear, peroxisomal,
mitochondrial and plasma membrane localisation sequences. Genes
for extra-cellular domains of cell surface proteins can be used for
detection by fluorescently labelled antibodies. Binding of
macromolecules in vivo can be detected through microscopy, relying
on the fluorophore-proximity-dependent fluorescence wavelength
shift called ‘fluorescence (also Förster) resonance energy transfer’
(FRET).
Most of the marker proteins are from non-mammalian organisms
where the translation machinery is adapted to the respective non-
mammalian profiles of codon frequencies. In human cells, unusual
codons, which are also called ‘hungry codons’, can slow down
translation and thereby reduce the efficiency of gene expression [26].
Thus, the optimization of codon frequencies for the genes, which are
born on mRNA vectors, is thought to be advantageous. If the
frequencies in a coding sequence are adjusted to match the human
codon usage profile, the sequence is said to be ‘humanized’. For the
reliable expression of DNA-delivered transgenes, optimization of the
coding sequence also involves the abrogation of consensus-predicted
sites for undesired binding of transcription factors exploiting the
degeneracy of the genetic code. However, in contrast to DNA-
delivered transgenes, this modification of the coding nucleotide
sequence is not required for mRNA produced in vitro using a DNA
template and purified RNA-polymerase, as no transcription factor
binding sites are known within mRNA. Consequently, as the removal
of transcription binding sites can compromise the optimal codon
choice, optimization of transgene expression is more straightforward
with mRNA vectors than with DNA vectors.
In tissue culture and animal experiments, fluorescent substances,
such as fluorescein, can be included into the vector complexes instead
of marker genes in order to visualise the area of distribution of vector
particles and also to visualize the intracellular trajectories of the vector
particles. In addition, fluorescent dyes can be targeted to transfected
cells through the fusion of the transgene products to the HaloTag®
peptide, which can bind fluorescent labels attached to the
HaloLinkTM adapter (Promega). Similarly, colloidal carbon (e.g., the
same as used as ink in tattoo parlours), can be added to the
administered vector preparations to mark the site of the vector
administration in vivo.
Particular features of the design of cell-fate
reprogramming mRNA vectors
Cell-fate reprogramming is used in regenerative medicine and
production of testing human tissue for high-throughput drug
screening. The requirements of these applications should be kept in
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mind while designing mRNA vector molecules and mRNA-based
vector complexes.
Cell-fate reprogramming through gene transfer for the needs
of regenerative medicine
It is widely appreciated that clinical regenerative medicine is
plagued by the scarcity of human donor tissue. Indeed, research in
stem cell technologies is driven, to a large extent, by the need for tissue
and cell material for transplantation.
Germ line cells are totipotent, that is, they have an epigenetic
potential to differentiate into all existing types of cells. To achieve the
goals of regenerative medicine, it is often sufficient to be in possession
of cells, which are pluripotent, that is, have an epigenetic potential to
differentiate into a number of specific types of cells. For example, cells
extracted from early stage embryos and propagated in vitro,
embryonic stem (ES) cells, are pluripotent. Various other strategies to
procure pluripotent cells are currently available. The choice of a
particular type of pluripotent cells is dictated by many parameters,
including ethical considerations, the number of initially available cells,
the number of cells required for the transplantation material, their
level of pluripotency, non-carcinogenicity and the availability of an
appropriate differentiation protocol. Regrettably, the use of highly
pluripotent ES cells, which are capable of highly reproducible
differentiation into a range of specific cell types, is mired with ethical
concerns related to human embryo destruction. In addition, ES cells
have a dangerous proclivity to produce teratomas after grafting in
vivo. Thus, the development of stringent methods for removal of
potentially tumorigenic undifferentiated cells in the human transplant
material (e.g., via engineering of inducible suicidal cell clean-up
systems) can be an appropriate strategy to generate safe transplant
material [27]. Favourably, pluripotent cells that are resident in adult
individuals, so-called ‘adult progenitor cells’, are not prone to
tumorigenesis. However, generation of transplantation material from
progenitor cells could be complicated by the scarcity of the patient-
derived starting cell material and by the absence of a reliable
differentiation protocol.
An important breakthrough in regenerative medicine has occurred
when it was shown that pluripotent cells can be produced artificially
by de-differentiation of adult differentiated cells in vitro [1]. De-
differentiation was achieved through the introduction of several
developmental genes into the cells and the resultant pluripotent cells
were named ‘induced pluripotent stem cells’ (iPS cells). At first, the iPS
cells were generated from fibroblasts [28,30]. Later, the techniques
were perfected to produce iPS cells from other cell types, e.g., T-
lymphocytes [31,32]. Issues affecting the successful generation of iPS
cells include mutations and DNA rearrangements in terminally
differentiated cells, both in the source cells, particularly in old adult
cell donors, and the cells growing in vitro. It was shown that the
generation of de novo mutations and chromosomal abnormalities can
be alleviated through incubation of the cells in hypoxic conditions,
where the burden of the mutagenic reactive oxygen species is reduced.
Reprogramming factors to produce iPS cells in the original
combination of K. Takahashi and S. Yamanaka were Oct3/4 (also
called Oct4), Sox2, Klf4, c-Myc, which were introduced with retroviral
vectors [1]. Later, iPS cells were successfully generated with the same
combination of transgenes using mRNA vectors [33]. Other formulas
of reprogramming factors were used to produce iPS cells, e.g., a
combination of Oct4, Sox2, LIN28 and Nanog [34,35]. The motivation
for the search of alternative de-differentiating combinations of factors
is driven by: 1) the desirability for increased efficiency of iPS cell
generation; 2) the unsafe potential of c-Myc to induce malignant
transformation [36]. Encouragingly, c-Myc-free combinations of
factors did not have a reduced reprogramming efficiency [37]. One
more practical option is the employment of a transformation-deficient
reprogramming-competent mutant version of c-Myc [38]. Various
source cells for the generation of iPS cells are expected to require
different optimal combinations of reprogramming developmental
factors [39,40].
After pluripotent cells are obtained in vitro or pinpointed in vivo,
the next issue on the therapeutic agenda is their differentiation into
specialized cells to confer the desired function to the human body.
Traditional differentiation protocols often depend on a combination
of various factors in the cell growth medium and a defined schedule of
their administration. A more recent approach for ‘coaxing’ of
pluripotent cells, such as iPS cells, into specific differentiation
pathways is their ‘forward programming’ using gene delivery [41], e.g.,
with mRNA vectors.
Clearly, the generation of transplantation material through de-
differentiation of specialized cells into iPS cells with their subsequent
differentiation into desired specialized cells is an elaborate and costly
strategy. Direct trans-differentiation of one type of specialized cells
into another type could be an attractive shortcut in the production of
cell grafts. In an important breakthrough, gene transfer-based direct
trans-differentiation, also called ‘direct reprogramming’, was used to
change postnatal cardiac or dermal fibroblasts into cardiomyocytes
without recourse to stem cells, using reprogramming factors GATA4,
Mef2c and Tbx5 [4]. So far, it was accomplished in several cell systems
in vitro and only recently in vivo [42]. Another group of researchers
achieved effectively similar trans-differentiation of embryonic
fibroblasts into cardiomyocytes using a protocol for epigenetic
reprogramming relying on the extreme shortening of the iPS-cell-
stage, the latter being attained through expression of the standard
combination of Oct4, Sox2, Klf4 and c-Myc transgenes [43].
Developments in protocols for direct reprogramming of patients’ cells
into cardiomyocytes have potentially high clinical significance [44,45].
Direct reprogramming was successfully accomplished in other types of
cells, with neurons and neuron-related cells obtained through trans-
differentiation of Sertoli cells [46], melanocytes [47] and fibroblasts
[48,49].
Once transgene combination required for trans-differentiation is
established ex vivo, the same gene cocktail can be delivered in vivo for
trans-differentiation in situ. Direct reprogramming through targeted
gene delivery in vivo is extremely attractive as therapeutic benefits of
regeneration can be achieved without the potential complications
associated with transplantation procedures. So, instead of using an
external graft, this healing strategy relies on the generation of the
replacement cells by in situ trans-differentiation of the patient’s own
cells. For example, the attained direct reprogramming of
cardiofibroblasts into cardiomyocytes in the heart [42] could be an
alternative to cardiac cell therapy, where the cell retention rate is often
low due to poor cell homing [50]. Thus, therapeutic epigenetic
reprogramming in vivo could become a safer and cheaper therapeutic
option than traditional transplantation technology. Indeed, in eye
conditions due to the degeneration of the neuroretina, it would be very
attractive to trans-differentiate retinal pigment epithelium (RPE) cells
into neuroretina cells after intraocular administration of a
reprogramming gene cocktail (of course, with the condition that RPE
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cells have not degenerated themselves); this procedure was successfully
accomplished in chicks [51]. Direct reprogramming through gene
delivery in vivo is also incomparably faster than the route with de-
differentiation and subsequent differentiation, as this latter route
unavoidably involves time-consuming cell expansion in vitro. In the
clinical setting, time is of the essence; for example, failure of pancreas
often requires urgent therapeutic intervention. Encouragingly, it was
possible to generate pancreatic cells through gene-transfer-mediated
trans-differentiation in vivo [52]. In conclusion, it appears that gene-
transfer in vivo, such as mRNA-mediated gene transfer in vivo, can
direct therapeutic trans-differentiation directly in the human body,
combining the advantages of autologous transplantation and in vivo
gene therapy.
Cell-fate reprogramming through gene transfer for the needs
of drug screening
Regenerative medicine is not the only medical field where donor
tissue is required. Another very important application for human
stem-cell derived material is high-throughput robotic screening of
chemical compound libraries to discover new drugs [53]. For example,
iPS cells can be used to generate fragments of human heart and these
fragments can be employed to screen extensive libraries of various
chemicals to find the best substances with the desired pharmacological
action [54]. Clearly, millions of heart disease patients could benefit
from the results of such screening.
Although cells of non-human origin, human-animal hybrid cells
and human cancer cells can be used for drug screening, undoubtedly,
the results obtained with non-cancerous human tissue offer more
reliable guidance on the potential value of a specific drug in human
medicine. In general, high quality human tissue material for drug
screening can be obtained through gene-transfer-led differentiation of
hES cells, donated human adult stem cells and in-vitro-generated iPS
cells. Advancing technologies might enable bespoke high-throughput
screening projects and the generation of personalised drugs using iPS-
cells-derived differentiated material or trans-differentiated material
from individual patients.
Where do mRNA-based vectors stay among other gene
vectors for cell-fate reprogramming?
Various types of gene vectors were used to deliver reprogramming
gene cocktails for iPS cell production (de-differentiation),
differentiation coaxing (forward programming) and trans-
differentiation. The majority of gene vector types leave a permanent
genetic trace in target cells because of the irreversible chromosomal
integration of their genetic material. Integration can be mediated by
specialized enzymatic machinery, e.g., in retroviral [55], lentiviral
vectors [56] and eukaryotic transposons [57]. After gene delivery with
some other vector types, such as plasmid vectors [58] or minicircle
vectors [59,60], chromosomal integration occurs through spontaneous
target-cell-mediated recombination. As remodelling of cell fate
requires only transient expression of the reprogramming factors and,
in fact, the continuously expressed transgenes are likely to interfere
with the desired epigenetic trajectory of the cells, permanent presence
of the transgenes within chromosomal DNA necessitates assembly and
employment of complicated inducible systems of transgene
expression. Another, even more serious, problem of chromosomal
integration events is their propensity to generate adverse mutations,
e.g., mutations leading to the malignant transformation.
Gene vectors providing the exclusive extra-chromosomal existence
of transgenes, so-called episomal vectors [61], might offer a solution to
the insertional mutagenesis problem. However, as expression of
developmental factors would, ideally, terminate in an eventual
shutdown, these vectors would still require genetic machinery for the
controlled end of transgene expression. In general, the ideal vectors for
genes to induce epigenetic switches should not just be episomal but
should possess a ‘hit-and-run’ property, leaving no genetic residue
after successful reprogramming. A permanent genetic trace can be
avoided with direct delivery of developmental factors in the form of
cell-permeable proteins to the cytoplasm of the target cells [62-64].
However, engineering cell-permeable versions of all the desired
developmental proteins could be cumbersome. Delivering the genetic
cargo directly to the cytoplasm can also be achieved with viral RNA-
carrying vectors, such as negative-strand-RNA-containing Sendai
virus vectors with ablated or temperature sensitive replication [65].
Notably, synthetic cytoplasmic gene delivery vectors, such as mRNA
vectors, appear to be the flexible tools required for ‘hit-and-run’
epigenetic reprogramming [66]. The perceived safety of synthetic
mRNA vectors in comparison to viral vectors is undoubtedly an
important feature, which can make mRNA vectors a favoured option
in the choice of the vector type for the clinical applications of
therapeutic epigenetic reprogramming. In addition, numerous genes
can be efficiently delivered simultaneously to target cells for co-
transfection with cocktails of synthetic mRNA vectors, while it might
be challenging to perform co-transduction with multiple viral vectors
in one go [67]. There are two general explanations, which can be
offered for the low efficiency of co-transduction with viral vectors.
Firstly, since individual viral vector particles penetrate the membrane
barrier of the target cells in an individual manner, their co-
transduction might follow the higher order reaction kinetics. Secondly,
co-transduction with some individual viral vectors could be distinctly
uncooperative because of the presence of infection interference
mechanisms in their cognate viruses and the incomplete inactivation
of these mechanisms in the descendant viral vectors. Synthetic mRNA
vectors have been used to establish a solid track record of efficient
gene delivery and, importantly, have been successfully employed for
cell fate reprogramming [66,68]. The upside of the mRNA vectors is
also the fact that their nucleic acid sequences are easily amenable for
chemical modification. Thus, mRNA vectors with some modified
nucleobases, which are known to reduce innate immune responses,
were shown to be effective tools of epigenetic reprogramming [69].
No doubt, delivery of developmental factors with mRNA vectors is
only one element in successful epigenetic switches. Cocktails of small
molecular weight chemicals and the addition of extracellular protein
factors can certainly be used to augment the transformation of the
epigenetic state through the action of mRNA vectors. In particular,
DNA de-methylation agents 5-azacytidine and zebularine were
reported to be capable of trans-differentiation enhancement [70],
while histone deacetylase inhibitor valproic acid was used to potentiate
de-differentiation [71]. In addition, cell fate reprogramming was
shown to be augmented by miRNAs [72]. Clearly, miRNAs can be
delivered in conjunction with mRNA. It is expected that robotic
systems for combinatorial screening can be used to search for suitable
reprogramming mixtures of mRNA vectors, protein factors, miRNAs
and small molecular weight molecules [72].
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Future perspectives
Undoubtedly, mRNA vectors should be a short-listed vector choice
for the generation of iPS cells and other epigenetically modified cells in
regenerative medicine and high-throughput drug screening with
artificial human tissues. Control of mRNA abundance during a short
time-frame immediately after the delivery of mRNA vectors to human
cells is a key feature, which makes them attractive to use for cell fate
reprogramming. In addition, clinical applications of mRNA-based
gene transfer, in particular generation of engraftment materials, draw
vital safety benefits from the non-mutagenic, ‘hit-and-run’ and
cytosol-targeted, gene delivery that is characteristic of mRNA vectors.
Further improvements in the design and production of mRNA
vectors for therapeutically important epigenetic switches are expected
and are likely to include:
• Development of more stable, highly deliverable and gene-
expression-proficient forms of mRNA vectors, incorporating
ligands for cell-specific targeting, efficient cell penetration and
positioning in the intracellular milieu and
• Automated screening for new cocktails of mRNA vectors and
other molecules for bespoke tasks of therapeutic epigenetic
reprogramming.
A very attractive goal in regenerative medicine is therapeutic trans-
differentiation in vivo with targeted delivery of reprogramming gene
vectors directly to the body site requiring a regenerative intervention.
So far in vivo trans-differentiation was achieved only in animal
models. The inherent safety of mRNA-based vectors might make them
a highly suitable tool for the transfer of the technology to human
patients.
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